83 related articles for article (PubMed ID: 16377504)
1. Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma.
Kim RD; Kundhal PS; McGilvray ID; Cattral MS; Taylor B; Langer B; Grant DR; Zogopoulos G; Shah SA; Greig PD; Gallinger S
J Am Coll Surg; 2006 Jan; 202(1):112-9. PubMed ID: 16377504
[TBL] [Abstract][Full Text] [Related]
2. Does the textbook outcome in pancreatic surgery score after pancreaticoduodenectomy for ampullary carcinoma have prognostic value?
Leech N; Krige JEJ; Sobnach S; Kloppers JC; Bernon MM; Burmeister S; Jonas EG
S Afr J Surg; 2024 May; 62(2):33-38. PubMed ID: 38838117
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Analysis and Prognostic Factors for Survival in Patients with Operable Ampullary Carcinoma: A Multi-Institutional Retrospective Experience.
Demirci NS; Cavdar E; Ozdemir NY; Yuksel S; Iriagac Y; Erdem GU; Odabas H; Hacibekiroglu I; Karaagac M; Ucar M; Ozturk B; Bozkaya Y
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38793001
[No Abstract] [Full Text] [Related]
4. Expression Profile of KRAS and p16 in Periampullary Cancer.
Tewari M; Swain JR; Mishra RR; Dixit VK; Shukla HS
Indian J Surg Oncol; 2024 Mar; 15(1):25-34. PubMed ID: 38511045
[TBL] [Abstract][Full Text] [Related]
5. Ampullary Cancer: Histological Subtypes, Markers, and Clinical Behaviour-State of the Art and Perspectives.
Nappo G; Funel N; Laurenti V; Stenner E; Carrara S; Bozzarelli S; Spaggiari P; Zerbi A
Curr Oncol; 2023 Jul; 30(7):6996-7006. PubMed ID: 37504367
[TBL] [Abstract][Full Text] [Related]
6. Remission from the 5-Fu-Based Chemotherapy to Gemcitabine-Based Chemotherapy-Based on the Pathological Classification of Periampullary Carcinoma: A Case Report and Literature Review.
Hu W; Duan Z; Zhang Y; Liu J; Bao J; Gao R; Tang Y; Liu T; Xiong H; Li W; Fu X; Liao S; Fang L; Liang B
Onco Targets Ther; 2022; 15():891-896. PubMed ID: 36046466
[TBL] [Abstract][Full Text] [Related]
7. Predictors and Recurrence Patterns After Radical Surgery in Ampulla of Vater Cancer: Comparative Analysis Between Early and Late Recurrence.
Zhang ZY; Liu DW; Hao DS; Zhou ZQ
Front Surg; 2022; 9():833373. PubMed ID: 35372475
[TBL] [Abstract][Full Text] [Related]
8. Choice of surgical procedures for patients with stage T1 carcinoma of the papilla of Vater: a retrospective study.
Gu Z; Li Z; Yu W; Zhang Y; Wang C
Transl Cancer Res; 2020 Nov; 9(11):7113-7124. PubMed ID: 35117316
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing patterns of recurrence following pancreaticoduodenectomy for patients with distal bile duct cancer and ampulla of Vater cancer.
Lee DH; Kim HJ; Cho CW; Yun SS; Lee DS
Ann Hepatobiliary Pancreat Surg; 2022 May; 26(2):138-143. PubMed ID: 35013007
[TBL] [Abstract][Full Text] [Related]
10. Treatment Approach to Adenocarcinoma of the Ampulla of Vater.
Patel M; Uboha NV
Curr Treat Options Oncol; 2021 Sep; 22(11):103. PubMed ID: 34586537
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F
Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676
[TBL] [Abstract][Full Text] [Related]
12. Impact of lymph node staging systems in predicting outcome in patients with ampullary cancer.
Saluja SS; Mishra PK; Kiran S; Shah HJ; Chandrasekar S; Nayeem M; Sharma A; Varshney VK
Ann Hepatobiliary Pancreat Surg; 2020 Nov; 24(4):484-495. PubMed ID: 33234752
[TBL] [Abstract][Full Text] [Related]
13. Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis.
Kamarajah SK; Bednar F; Cho CS; Nathan H
J Gastrointest Surg; 2021 Jul; 25(7):1805-1814. PubMed ID: 33230687
[TBL] [Abstract][Full Text] [Related]
14. Predictors of early recurrence following a curative resection in patients with a carcinoma of the ampulla of Vater.
Ma CH; Lee JH; Song KB; Hwang DW; Kim SC
Ann Surg Treat Res; 2020 Nov; 99(5):259-267. PubMed ID: 33163455
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors of Long-term Survival Following Radical Resection for Ampullary Carcinoma.
Vilhordo DW; Gregório C; Valentini DF; Edelweiss MIA; Uchoa DM; Osvaldt AB
J Gastrointest Cancer; 2021 Sep; 52(3):872-881. PubMed ID: 32808236
[TBL] [Abstract][Full Text] [Related]
16. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma.
Zimmermann C; Wolk S; Aust DE; Meier F; Saeger HD; Ehehalt F; Weitz J; Welsch T; Distler M
Sci Rep; 2019 Sep; 9(1):12676. PubMed ID: 31481741
[TBL] [Abstract][Full Text] [Related]
17. Primary small bowel adenomas and adenocarcinomas-recent advances.
Maguire A; Sheahan K
Virchows Arch; 2018 Sep; 473(3):265-273. PubMed ID: 29998424
[TBL] [Abstract][Full Text] [Related]
18. Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy.
He C; Mao Y; Wang J; Duan F; Lin X; Li S
BMC Cancer; 2018 Mar; 18(1):327. PubMed ID: 29580215
[TBL] [Abstract][Full Text] [Related]
19. Determining the Adequate Examined Lymph Node Count in Resected Ampullary Adenocarcinoma-A National Cohort Study.
Nassour I; Christie A; Choti MA; Mansour JC; Minter RM; Polanco PM; Augustine MM; Porembka MR; Xie XJ; Wang SC
J Gastrointest Surg; 2018 May; 22(5):792-801. PubMed ID: 29546687
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
